VTUS Share Price

Open 1.44 Change Price %
High 1.46 1 Day 0.01 0.69
Low 1.39 1 Week 0.00 0.00
Close 1.45 1 Month 0.00 0.00
Volume 220392 1 Year 0.00 0.00
52 Week High 49.76
52 Week Low 48.49
VTUS Important Levels
Resistance 2 1.51
Resistance 1 1.49
Pivot 1.43
Support 1 1.41
Support 2 1.39
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Ventrus Biosciences, Inc. (NASDAQ: VTUS)

VTUS Technical Analysis 2.5
As on 11th Jul 2014 VTUS Share Price closed @ 1.45 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.31 & Strong Buy for SHORT-TERM with Stoploss of 1.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
VTUS Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
VTUS Other Details
Segment EQ
Market Capital 35828148.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.ventrusbio.com
VTUS Address
VTUS
99 Hudson Street
5th Floor
New York, NY 10013
United States
Phone: 646-706-5208
Fax: 646-706-5101
Interactive Technical Analysis Chart Ventrus Biosciences, Inc. ( VTUS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ventrus Biosciences, Inc.
VTUS Business Profile
Ventrus Biosciences, Inc. (Ventrus) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Its product candidate portfolio consists of three late-stage drugs intended to treat these conditions: one new chemical entity (NCE) and two previously approved molecules that will have market exclusivity for new and patentable topical gastrointestinal indications. The Company�s three late-stage product candidates are Iferanserin ointment (VEN 309) for the treatment of hemorrhoids, Diltiazem cream (VEN 307), a treatment for the relief of pain associated with anal fissures and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis (IPAA). On November 14, 2011, the Company acquired Sam Amer & Co.